No more than 10% of prescriptions allowing generic drug substitution will actually be switched with copy medicines at the dispensing pharmacist, Masaki Muto, executive managing director of the Japan Society of Generic Medicines told the recent CPhI Worldwide meeting, an international convention on pharmaceutical ingredients and intermediates, in Tokyo.
Despite government moves to promote the use of copy drugs (Marketletter passim), he noted that generic substitution is particularly unlikely when the approved indications for these are different to the original drugs.
Dr Muto went on to tell delegates that the percentage of patients who prefer generics will not be that great, despite the introduction of the new prescription form that permits substitution unless specifically contraindicated by checking off a designated box.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze